Abstract: A drug carrier with a property of crossing the blood-brain barrier comprises an extracellular vesicle with a human leukocyte antigen-G antibody on its surface. This carrier can serve as a pharmaceutical composition for promoting apoptosis of brain tumor cells, inhibiting growth of brain tumor cells, or reducing expression of O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells. These effects contribute to the treatment of glioblastoma multiforme (GBM).

Abstract: The present disclosure provides a fusion protein and the nucleic acid encoding sequence thereof, and uses of the same. The fusion protein of the present disclosure achieves the effect of treating cancer, immunoregulation and activating immune cells through various efficacy experiments.

Abstract: A BAG6 specific chimeric antigen receptor, a nucleic acid, a BAG6 specific chimeric antigen receptor expression plasmid, a BAG6 specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the BAG6 specific chimeric antigen receptor expressing cell are provided. The BAG6 specific chimeric antigen receptor specifically binds to BCL2 associated athanogene 6 (BAG6). The nucleic acid encodes the BAG6 specific chimeric antigen receptor. The BAG6 specific chimeric antigen receptor expression plasmid expresses the BAG6 specific chimeric antigen receptor. The BAG6 specific chimeric antigen receptor expressing cell is obtained by transducing the BAG6 specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the BAG6 specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

Abstract: A solution for preserving extracellular vesicles/exosomes has a carrier solvent selected from a group consisting of polysorbate 80, sucrose, and polyethylene glycol 3350/4000; and a stabilizer selected from a group consisting of salts, amino acids, and amino acid salts; wherein the pH of the preservation solution ranges from 5 to 7.4.

Abstract: The present disclosure provides an anti-tumor antigen nanobody that specifically binds to a human leukocyte antigen-G. The present disclosure also provides the nucleic acid sequence of the anti-tumor antigen nanobody, use of the anti-tumor antigen nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of HLA-G.

Abstract: Present invention is related to a tumor microenvironment on chip or a biochip for cell therapy having a carrier, a first cell or tissue culture area and a second cell or tissue area imbedded within the carrier. The present invention provides a biochip successfully cooperating micro fluidic technology and cell culture achieving the goal for detecting or testing the function of cell therapy for cancer or tumor.

Abstract: The present disclosure provides an immunomodulation and anti-tumor-related nanobody that specifically binds to a human leukocyte antigen-G, a programmed cell death ligand 1, and CD3 ?. The present disclosure also provides the nucleic acid sequence of the immunomodulation and anti-tumor-related nanobody, and use of the immunomodulation and anti-tumor-related nanobody for treating cancer and immune-related disorders.

Abstract: The present disclosure provides an anti-T-cell nanobody that specifically binds to CD3 ?. The present disclosure also provides the nucleic acid sequence of the anti-T-cell nanobody, use of the anti-T-cell nanobody for treating cancer, immunoregulation and activating immune cells, and a method for detecting expression levels of CD3 ?.

Abstract: A method for producing exosomes in a large-scale by using a cyclic tensile bioreactor to stimulate cells to release exosomes. In addition, the exosome having an anti-HLA-G protein specific for cancer is used as a delivery vehicle to deliver therapeutic agents for treating cancer.

Abstract: The present disclosure provides an anti-immune-checkpoint nanobody that specifically binds to a programmed cell death ligand 1. The present disclosure also provides the nucleic acid sequence of the anti-immune-checkpoint nanobody, use of the anti-immune-checkpoint nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of PD-L1.

Abstract: A multispecific nanobodies chimeric antigen receptor and T-cell engager includes an HLA-G nanobody chimeric antigen receptor and a bispecific T-cell engager. The HLA-G nanobody chimeric antigen receptor includes an HLA-G nanobodies unit, a transmembrane domain, and a CD3z signaling domain. The bispecific T-cell engager includes a PD-L1 nanobodies unit and a CD3e nanobody.

Abstract: The present disclosure relates to a chimeric antigen receptor, a nucleic acid, a chimeric antigen receptor expression plasmid, a chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the chimeric antigen receptor expressing cell. The chimeric antigen receptor is specific to human leukocyte antigen G. The nucleic acid encodes the chimeric antigen receptor. The chimeric antigen receptor expression plasmid expresses the chimeric antigen receptor. The chimeric antigen receptor expressing cell is obtained by transducing the chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

Abstract: Present invention is related to a tumor microenvironment on chip or a biochip for cell therapy having a carrier, a first cell or tissue culture area and a second cell or tissue area imbedded within the carrier. The present invention provides a biochip successfully cooperating micro fluidic technology and cell culture achieving the goal for detecting or testing the function of cell therapy for cancer or tumor.

Abstract: The present disclosure relates to a HLA-G specific chimeric antigen receptor, a nucleic acid, a HLA-G specific chimeric antigen receptor expression plasmid, a HLA-G specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the HLA-G specific chimeric antigen receptor expressing cell. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expression plasmid expresses the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expressing cell is obtained by transducing the HLA-G specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the HLA-G specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

Abstract: The present disclosure provides an anti-immune-checkpoint nanobody that specifically binds to a programmed cell death ligand 1. The present disclosure also provides the nucleic acid sequence of the anti-immune-checkpoint nanobody, use of the anti-immune-checkpoint nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of PD-L1.

Abstract: The present disclosure provides an immunomodulation and anti-tumor-related nanobody that specifically binds to a human leukocyte antigen-G, a programmed cell death ligand 1, and CD3 ?. The present disclosure also provides the nucleic acid sequence of the immunomodulation and anti-tumor-related nanobody, and use of the immunomodulation and anti-tumor-related nanobody for treating cancer and immune-related disorders.

Abstract: The present disclosure provides an anti-tumor antigen nanobody that specifically binds to a human leukocyte antigen-G. The present disclosure also provides the nucleic acid sequence of the anti-tumor antigen nanobody, use of the anti-tumor antigen nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of HLA-G.

Abstract: The present disclosure provides an anti-T-cell nanobody that specifically binds to CD3 ?. The present disclosure also provides the nucleic acid sequence of the anti-T-cell nanobody, use of the anti-T-cell nanobody for treating cancer, immunoregulation and activating immune cells, and a method for detecting expression levels of CD3 ?.

Abstract: The present disclosure relates to a HLA-G specific chimeric antigen receptor, a nucleic acid, a HLA-G specific chimeric antigen receptor expression plasmid, a HLA-G specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the HLA-G specific chimeric antigen receptor expressing cell. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expression plasmid expresses the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expressing cell is obtained by transducing the HLA-G specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the HLA-G specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

Abstract: The present disclosure relates to a chimeric antigen receptor, a nucleic acid, a chimeric antigen receptor expression plasmid, a chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the chimeric antigen receptor expressing cell. The chimeric antigen receptor is specific to human leukocyte antigen G. The nucleic acid encodes the chimeric antigen receptor. The chimeric antigen receptor expression plasmid expresses the chimeric antigen receptor. The chimeric antigen receptor expressing cell is obtained by transducing the chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.